Abstract
Background Capsular contracture is the most common complication associated with silicone prostheses. It may take the form of anything from slight hardening to obvious deformity. The role of transforming growth factor β (TGF-β) in the scar physiopathology of any fibrotic process has been demonstrated. The effects of inhibition of TGF-β have also been demonstrated in experimental models of fibrosis, which opens the way for new therapeutic alternatives in the treatment of capsular contracture. The aim of this study was to evaluate periprosthetic fibrosis with a newly synthesized TGF-β peptide inhibitor (p144®). Methods Three experimental groups were formed: Group I, subcutaneous and submuscular textured silicone prostheses were left untreated; Group 2, the prostheses were left after being immersed in the vehicle; Group 3, the same protocol was followed as in Group 2, but the solution contained the vehicle with the inhibitor peptide of TGF-β, p144 (15 mg/prosthesis). The animals were sacrificed 24 weeks after implantation, and the capsules were assessed both macroscopically and histologically. Results The results obtained showed that the inhibition of capsular thickness and soluble collagen content in pericapsular fibrosis did not significantly decrease in the group of animals treated with the TGF-β inhibitor peptide in comparison with control cases. Conclusions We detected no statistically significant reduction in fibrosis in the periprosthetic capsule after treating the implants with the inhibitor peptide p144, but we feel that the influence of trauma around the prosthesis is critical in impeding the antifibrotic activity of the inhibitor peptide.

This publication has 33 references indexed in Scilit: